Your search for hematologic malignancies matches 231 pages

Showing 201 - 231


hematologic malignancies
leukemia
myelodysplastic syndromes

Past Exposure to Thiopurines Associated With Increased Risk of Myeloid Disorders in Patients With Inflammatory Bowel Disease

Past exposure to immunosuppressive drugs called thiopurines has been found to increase the risk of myeloid disorders, such as acute myeloid leukemia and myelodysplastic syndrome, among patients with inflammatory bowel disease (IBD). The findings were reported by Lopez et al in Clinical...

hematologic malignancies

Ruxolitinib Granted Priority Review for Polycythemia Vera

The U.S. Food and Drug Administration (FDA) has accepted for filing and granted Priority Review to the supplemental New Drug Application (sNDA) for ruxolitinib (Jakafi) as a potential treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of...

hematologic malignancies
lymphoma

Results of Genomic Analysis Suggest Strategy for Overcoming Ibrutinib Resistance in Mantle Cell Lymphoma

Although the Bruton tyrosine kinase (BTK) inhibitor ibrutinib (Imbruvica) has shown unprecedented clinical activity in mantle cell lymphoma, about 32% of patients do not respond to the drug and majority of responders eventually relapse. Genomic sequencing of tumor and healthy tissue from patients...

hematologic malignancies
leukemia

Minimal Residual Disease–Based Risk-Directed Therapy Is Effective in Children With BCR-ABL1–Like B-Cell ALL

BCR-ABL1–like acute lymphoblastic leukemia (ALL), a recently identified B-cell ALL subtype associated with poor outcome, has a gene-expression profile similar to BCR-ABL1–positive disease without the presence of the BCR-ABL1 fusion protein. In a retrospective analysis reported in the...

hematologic malignancies

Anti–IL-6 Antibody Siltuximab Produces Durable Responses in Multicentric Castleman's Disease

Multicentric Castleman’s disease is characterized by overproduction of interleukin-6 (IL-6). In a trial reported in The Lancet Oncology, van Rhee et al found that the anti–IL-6 antibody siltuximab (Sylvant) produced a significantly better response rate vs placebo in patients with the...

hematologic malignancies
leukemia
lymphoma

FDA Approves Idelalisib for Three Types of Blood Cancers

The U.S. Food and Drug Administration (FDA) has approved idelalisib (Zydelig) for the treatment of patients with three types of blood cancers. Idelalisib is being granted traditional approval to treat patients with relapsed chronic lymphocytic leukemia (CLL). Used in combination with rituximab...

hematologic malignancies

Improved Survival in Hematologic Malignancies in Europe Between 1997 and 2008

As reported by Sant et al in The Lancet Oncology, the population based EUROCARE-5 study has shown significantly improved survival in hematologic malignancies in Europe between 1997 and 2008. Although improved, survival was poorer in Eastern Europe compared with other regions. Study Details This...

hematologic malignancies
leukemia

Researchers Identify Events Causing Bone Marrow Inflammation Leading to Blood Disorders

According to a new study, a cascade of molecular events in the bone marrow produces high levels of inflammation that disrupt normal blood formation and lead to potentially deadly disorders including leukemia. The discovery, published by the journal Cell Stem Cell, points the way to potential...

hematologic malignancies
lymphoma

Early Evidence Suggests Proton Therapy May Offer Safe, Long-Term Treatment for Hodgkin Lymphoma

Despite some success in treating patients with Hodgkin lymphoma, many patients may experience late effects of radiation therapy and chemotherapy treatment, including the possible onset of breast cancer or heart disease. A study by Hoppe et al from the University of Florida Proton Therapy Institute...

hematologic malignancies

Epigenetically Reprogrammed Cells Generate Functional Cord Blood Stem Cells for Transplantation

The use of cord blood cells as hematopoietic stem cell grafts for patients with hematologic malignancies receiving an allogeneic stem cell transplant has been limited to children due to the small number of stem cells present in a single cord blood collection. The result of these limitations has...

hematologic malignancies
supportive care

Addition of Tigecycline to Empiric Therapy Improves Success Rate in Febrile Neutropenic Patients With Hematologic Malignancy

Antibiotic monotherapy is considered standard in empiric therapy in febrile neutropenic cancer patients, but the approach may be insufficient given the increase in infections due to multidrug-resistant microorganisms. Tigecycline (Tygacil), the first in a new class of glycylcycline antibiotics, has ...

hematologic malignancies
leukemia
lymphoma

Investigational Bromodomain Inhibitor Shows Clinical Activity in Some Blood Cancers

The results from a phase I study of a new investigational epigenetic therapy called OTX015, a small-molecule inhibitor that blocks the activity of bromodomain and extraterminal (BET)-bromodomain proteins, is showing clinical activity in some blood cancers, including leukemia and lymphoma. The study ...

issues in oncology
hematologic malignancies
leukemia

CD49d-Positivity Is the Strongest Flow Cytometry–Based Predictor of Overall Survival in CLL

In a study reported in the Journal of Clinical Oncology, Bulian et al found that CD49d-positive chronic lymphocytic leukemia (CLL) patients have significantly poorer overall survival and treatment-free survival and that CD49d status is the strongest flow cytometry–based predictor of overall...

health-care policy
hematologic malignancies
issues in oncology
issues in oncology

Choosing Wisely® Initiative Improves Quality and Cost of Care

Five commonly used hematology tests, treatments, and procedures are not always necessary, according to the Choosing Wisely® initiative of the ABIM (American Board of Internal Medicine) Foundation. The American Society of Hematology (ASH) Choosing Wisely list of these five tests was...

hematologic malignancies
leukemia

Obinutuzumab/Chlorambucil Superior to Rituximab/Chlorambucil as First-Line Treatment for Older CLL Patients With Comorbidities

Obinutuzumab (Gazyva) plus chlorambucil (Leukeran) was superior to rituximab (Rituximab) plus chlorambucil as first-line therapy in older chronic lymphocytic leukemia (CLL) patients with comorbidities, with an acceptable safety profile, according to final results of the phase III CLL11 trial....

hematologic malignancies

Reduced-Intensity Hematopoietic Stem Cell Transplant Spares Cognition

The intensity of transplant-related chemotherapy and radiation has effects on cognition, according to a study presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition (Abstract 913). Full-intensity hematopoietic stem cell transplant was associated with cognitive...

hematologic malignancies
leukemia
lymphoma

Successful Chimeric Antigen Receptor–Expressing T-Cell Treatment Reported in Advanced Lymphomas

Development of autologous genetically engineered anti-CD19 chimeric antigen receptor (CAR)-expressing T cells holds promise in the treatment of hematologic malignancies. CAR T cells are being studied in adult and pediatric acute lymphocytic leukemias and in chronic lymphocytic leukemia, and...

hematologic malignancies

Study Finds Possible Link Between Allergies and Increased Risk of Hematologic Cancers in Women

A team of researchers looking into the interplay of the immune system and cancer have found a link between a history of airborne allergies—in particular to plants, grass, and trees—with risk of blood cancers in women. The same association was not found in men, suggesting a possible...

hematologic malignancies
leukemia

Gemtuzumab Ozogamicin Reduces Minimal Residual Disease in Children With High-Risk Acute Myeloid Leukemia

Combining gemtuzumab ozogamicin (Mylotarg) with conventional chemotherapy may improve the outcome of bone marrow transplantation for some children battling high-risk acute myeloid leukemia (AML), according to a study led by St. Jude Children’s Research Hospital. The results appear in the...

hematologic malignancies
leukemia
issues in oncology

Novel Oncogenetic Classifier Identifies Low- and High-Risk Patients With Adult T-Cell Acute Lymphoblastic Leukemia

The Group for Research in Adult Acute Lymphoblastic Leukemia (GRAALL) recently reported significantly better outcome in T-cell acute lymphoblastic leukemia (ALL) harboring NOTCH1 or FBXW7 (N/F) mutations, although relapse was still observed in one-third of patients with N/F-mutated T-cell ALL. In a ...

hematologic malignancies
supportive care

Atorvastatin May Prevent Graft-vs-Host Disease in Allogeneic Stem Cell Transplant Recipients

Because statins exhibit immunomodulatory and anti-inflammatory effects that may ameliorate graft-vs-host disease, they may be a safe strategy following allogeneic hematopoietic cell transplantation. In a phase II study reported in the Journal of Clinical Oncology, Mehdi Hamadani, MD, and colleagues ...

hematologic malignancies
leukemia

NCCN: Practical Considerations in Selecting Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia

Although imatinib (Gleevec) is the initial therapy for chronic myeloid leukemia (CML), several second-generation tyrosine kinase inhibitors are now approved for the treatment of this disease. Michael Millenson, MD, of Fox Chase Cancer Center in Philadelphia, reviewed practical considerations in...

hematologic malignancies
lymphoma

NCCN: PET-Guided Therapy for Hodgkin Lymphoma Moving Into Clinical Practice

Interim positron emission tomography (PET) scan is being used to guide risk-adapted therapy in patients with early-stage and advanced-stage Hodgkin lymphoma for clinical research at academic centers, and experts predict that this will become standard of care in clinical practice. At the NCCN 8th...

hematologic malignancies
leukemia

Technologies for Monitoring Minimal Residual Disease May Help Predict Outcomes for Patients with Leukemia

New evidence suggests that using advanced genetics technologies to monitor for remaining cancer cells after treatment may soon become an effective tool to inform treatment decisions and ultimately predict patient outcomes for patients with a particularly aggressive form of acute lymphocytic...

hematologic malignancies
leukemia

High Rate of Durable Remissions with BTK Inhibitor Ibrutinib in Patients with Relapsed Chronic Lymphocytic Leukemia

Durable remissions are uncommon with current treatments for relapsed chronic lymphocytic leukemia (CLL). Bruton’s tyrosine kinase (BTK) is an essential component of B-cell receptor signaling that mediates interactions with the tumor microenvironment and promotes survival and proliferation of...

hematologic malignancies

Critically Ill Patients with Hematologic Malignancies Admitted to ICU Have Good Survival, Disease Control, and Quality of Life

A large prospective multicenter cohort study in France and Belgium, reported by the Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique, has shown that critically ill patients with hematologic malignancies admitted to the intensive care unit (ICU) have good survival,...

hematologic malignancies

FDA Grants Orphan Drug Status for Novel Targeted Therapy for the Treatment of Rare Hematologic Cancer

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to Stemline Therapeutics' SL-401 for the treatment of blastic plasmacytoid dendritic cell neoplasm, a rare and aggressive hematologic malignancy for which there is no effective treatment. SL-401 also has Orphan Drug...

hematologic malignancies

New Research Shows Significant Improvement in Overall Survival Outcomes for Patients Receiving Blood Stem Cell Transplants

Survival rates have increased significantly among patients who received blood stem cell transplants from both related and unrelated donors, according to a study published in the Journal of Clinical Oncology. The study authors attribute the increase to several factors, including advances in HLA...

hematologic malignancies
leukemia
lymphoma

St. Jude Children's Research Hospital Announces Issuance of U.S. Patent for Genetically Modified Human Immune Cells for Cancer Therapy

The United States Patent and Trademark Office today awarded St. Jude Children's Research Hospital U.S. patent number 8,399,645 for its invention of compositions for genetically modifying human immune cells so they can destroy some of the most common forms of cancer in children and adults. "This...

hematologic malignancies
leukemia
survivorship

Risk of Leukemia After Cancer Chemotherapy Persists

While advancements in cancer treatment over the last several decades have improved patient survival rates for certain cancers, some patients remain at risk of developing treatment-related leukemia, according to results of a study published online in Blood, the Journal of the American Society of...

hematologic malignancies

Ezatiostat Gets Orphan Designation for Treatment of Myelodysplastic Syndrome

Telik, Inc, announced that its product candidate, ezatiostat hydrochloride (Telintra), has been granted orphan drug designation by the FDA for the treatment of myelodysplastic syndrome (MDS). Ezatiostat is an investigational agent in development for the treatment of MDS and idiopathic chronic...